RMD Open
a lower risk of flare in patients with RA. Importantly, our findings suggest that the achievement of CliDR may modify the risk associated with treatment tapering, iden- tifying a patient subgroup in which de-escalation could be safely considered. While these results require valida- tion in larger, multicentre RCTs to establish causality and address potential confounding, they underscore the prognostic value of a stringent remission criterion. Contributors HL and MZ performed data collection and analysis. HL drafted the manuscript. HZ and CL participated in data collection. JG revised the manuscript. YJ and RL conceived the study and revised the manuscript. All authors approved the submitted version. RL is the guarantor of this work. Funding This work was supported by The National Key R&D Program of China (2022YFC3602000) and The National Natural Science Foundation of China (92374202). Competing interests None declared. Patient consent for publication Not applicable. Ethics approval This study involves human participants. This study was approved by the institutional research ethics committee of the Peking University People’s Hospital (No. 2018PHB006-01). Participants gave informed consent to participate in the study before taking part. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available upon reasonable request. The data that support the findings of this study contain sensitive patient health information and are subject to privacy regulations under the ethical approval granted for this research. Therefore, they are not publicly available. Deidentified data can be made available to qualified researchers on reasonable request, subject to the approval of the institutional ethics committee and the execution of a data use agreement. Requests should be directed to the corresponding author at liru@pkuph.edu.cn. Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/.
Arthritis for their use as clinical trial end points. Arthritis Rheumatol 2017;69:518–28. 8 Liu J-J, Li R, Gan Y-Z, et al . Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. Chin Med J (Engl) 2019;132:1009–14. 9 Sun X, Li R, Cai Y, et al . Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg Health West Pac 2021;15:100240. 10 Wells G, Becker J-C, Teng J, et al . Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954–60. 11 Smolen JS, Landewé RBM, Bergstra SA, et al . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3–18. 12 England BR, Smith BJ, Baker NA, et al . 2022 American College of Rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Rheumatol 2023;75:1299–311. 13 Lau CS, Chia F, Dans L, et al . 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J of Rheum Dis 2019;22:357–75. 14 Tageldin M, Wilson N, Yin Y, et al . A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort. Rheumatology (Oxford ) 2023;62:iv8–13. 15 Holten K, Paulshus Sundlisæter N, Sexton J, et al . Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials. RMD Open 2024;10:e004444. 16 Lillegraven S, Paulshus Sundlisæter N, Aga A-B, et al . Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Ann Rheum Dis 2023;82:1394–403. 17 Lafita FR. In RA in remission for >1 y, tapering TNFi to discontinuation did not meet noninferiority criteria compared with stable TNFi for disease flare at 12 mo. Ann Intern Med 2023;176:JC139. 18 Tascilar K, Hagen M, Kleyer A, et al . Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol 2021;3:e767–77. 19 Kuijper TM, Lamers-Karnebeek FBG, Jacobs JWG, et al . Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol 2015;42:2012–22. 20 Schett G, Emery P, Tanaka Y, et al . Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016;75:1428–37. 21 Tanaka Y, Smolen JS, Jones H, et al . The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Res Ther 2019;21:164. 22 Norvang V, Brinkmann GH, Yoshida K, et al . Achievement of remission in two early rheumatoid arthritis cohorts implementing different treat-to-target strategies. Arthritis Rheumatol 2020. 23 Emery P, Burmester GR, Naredo E, et al . Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann Rheum Dis 2020;79:1023–30. 24 Hirata S, Saito K, Kubo S, et al . Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther 2013;15:R135. 25 Dale J, Stirling A, Zhang R, et al . Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis 2016;75:1043–50. 26 Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, et al . Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial. JAMA 2019;321:461–72. 27 Sun Y, Lin J, Chen W. Artificial intelligence in rheumatoid arthritis. Rheumatol Autoimmun 2025;5:88–100.
ORCID iDs Haihui Li https://orcid.org/0009-0005-0274-3996 Huaqun Zhu https://orcid.org/0000-0001-9146-3753
REFERENCES 1 Smolen JS, Aletaha D, Bijlsma JWJ, et al . Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7. 2 Kjørholt KE, Sundlisæter NP, Aga A-B, et al . Three-year results of tapering tumor necrosis factor inhibitor to withdrawal compared to stable tumor necrosis factor inhibitor among patients with rheumatoid arthritis in sustained remission: a multicenter randomized trial. Arthritis Rheumatol 2025;77:1327–36. 3 Lillegraven S, Paulshus Sundlisæter N, Aga A-B, et al . Effect of Half- Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial. JAMA 2021;325:1755–64. 4 Einarsson JT, Willim M, Ernestam S, et al . Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a nationwide study in Sweden. Rheumatology (Oxford) 2019;58:227–36. 5 Smolen JS, Breedveld FC, Schiff MH, et al . A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57. 6 Aletaha D, Nell VPK, Stamm T, et al . Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806. 7 Mack ME, Hsia E, Aletaha D. Comparative assessment of the different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid
8
Li H, et al . RMD Open 2026; 12 :e006387. doi:10.1136/rmdopen-2025-006387
Powered by FlippingBook